BioLineRx Ltd.

TASE:BLRX Stock Report

Market Cap: ₪181.1m

BioLineRx Management

Management criteria checks 2/4

BioLineRx's CEO is Phil Serlin, appointed in Oct 2016, has a tenure of 7.58 years. total yearly compensation is $952.00K, comprised of 29.4% salary and 70.6% bonuses, including company stock and options. directly owns 0.014% of the company’s shares, worth ₪25.96K. The average tenure of the management team and the board of directors is 7.3 years and 2.4 years respectively.

Key information

Phil Serlin

Chief executive officer

US$952.0k

Total compensation

CEO salary percentage29.4%
CEO tenure7.6yrs
CEO ownership0.01%
Management average tenure7.3yrs
Board average tenure2.4yrs

Recent management updates

Recent updates

Does BioLineRx (TLV:BLRX) Have A Healthy Balance Sheet?

Apr 02
Does BioLineRx (TLV:BLRX) Have A Healthy Balance Sheet?

BioLineRx (TLV:BLRX) Has Debt But No Earnings; Should You Worry?

Aug 25
BioLineRx (TLV:BLRX) Has Debt But No Earnings; Should You Worry?

Health Check: How Prudently Does BioLineRx (TLV:BLRX) Use Debt?

Apr 05
Health Check: How Prudently Does BioLineRx (TLV:BLRX) Use Debt?

Is BioLineRx (TLV:BLRX) A Risky Investment?

Jun 17
Is BioLineRx (TLV:BLRX) A Risky Investment?

Is BioLineRx (TLV:BLRX) Using Debt In A Risky Way?

Feb 26
Is BioLineRx (TLV:BLRX) Using Debt In A Risky Way?

Is BioLineRx (TLV:BLRX) Using Debt In A Risky Way?

Oct 17
Is BioLineRx (TLV:BLRX) Using Debt In A Risky Way?

CEO Compensation Analysis

How has Phil Serlin's remuneration changed compared to BioLineRx's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$952kUS$280k

-US$61m

Sep 30 2023n/an/a

-US$52m

Jun 30 2023n/an/a

-US$43m

Mar 31 2023n/an/a

-US$32m

Dec 31 2022US$1mUS$297k

-US$25m

Sep 30 2022n/an/a

-US$24m

Jun 30 2022n/an/a

-US$22m

Mar 31 2022n/an/a

-US$22m

Dec 31 2021US$903kUS$290k

-US$27m

Sep 30 2021n/an/a

-US$35m

Jun 30 2021n/an/a

-US$34m

Mar 31 2021n/an/a

-US$34m

Dec 31 2020US$958kUS$250k

-US$30m

Sep 30 2020n/an/a

-US$28m

Jun 30 2020n/an/a

-US$27m

Mar 31 2020n/an/a

-US$26m

Dec 31 2019US$678kUS$256k

-US$25m

Sep 30 2019n/an/a

-US$21m

Jun 30 2019n/an/a

-US$24m

Mar 31 2019n/an/a

-US$23m

Dec 31 2018US$846kUS$254k

-US$23m

Sep 30 2018n/an/a

-US$25m

Jun 30 2018n/an/a

-US$26m

Mar 31 2018n/an/a

-US$26m

Dec 31 2017US$612kUS$240k

-US$24m

Compensation vs Market: Phil's total compensation ($USD952.00K) is above average for companies of similar size in the IL market ($USD436.57K).

Compensation vs Earnings: Phil's compensation has been consistent with company performance over the past year.

CEO

Phil Serlin (63 yo)

7.6yrs

Tenure

US$952,000

Compensation

Mr. Philip A. Serlin, also known as Phil, CPA, MBA has been the Chief Executive Officer at BioLineRx, Ltd., since October 10, 2016. Mr. Serlin served as the Chief Financial and Operating Officer of BioLine...

Leadership Team

NamePositionTenureCompensationOwnership
Philip Serlin
Chief Executive Officer7.6yrsUS$952.00k0.014%
$ 26.0k
Mali Zeevi
Chief Financial Officer7.6yrsUS$443.00k0.027%
$ 49.6k
Ella Sorani
Chief Development Officer7.3yrsUS$520.00k0.0055%
$ 10.0k
Holly May
President of BioLineRx USA1.9yrsUS$1.01mno data
John Lacey
Head of Corporate Communications & Investor Relationsno datano datano data
Tsipi Keren-Lehrer
Head of BD & Strategic Advisor4.8yrsno datano data
Raziel Fried
Treasurer & Budgetary Control Directorno datano datano data

7.3yrs

Average Tenure

58yo

Average Age

Experienced Management: BLRX's management team is seasoned and experienced (7.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Aharon Schwartz
Chairman of the Board20.3yrsno data0.31%
$ 559.4k
Sandra Panem
Director10.3yrsno datano data
Avraham Molcho
Independent External Director13.8yrsUS$26.55kno data
Raphael Hofstein
Director21.3yrsUS$140.92kno data
Ronald Levy
Member of Immuno-Oncology Scientific Advisory Board2.4yrsno datano data
Rami Dar
Independent External Director1.8yrsno datano data
Gal Cohen
Independent Directorless than a yearno datano data
Barbar-Jean Bormann-Kennedy
Director10.8yrsno datano data
Jon Marc Wigginton
Member of Immuno-Oncology Scientific Advisory Board2.4yrsno datano data
Ignacio Melero
Member of Immuno-Oncology Scientific Advisory Board2.4yrsno datano data
Aurelien Marabelle
Member of Immuno-Oncology Scientific Advisory Board2.4yrsno datano data
Shaoyu Yan
Directorless than a yearno datano data

2.4yrs

Average Tenure

65yo

Average Age

Experienced Board: BLRX's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.